New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;FB;PMFG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
May 29, 2015
16:19 EDTBMYOn The Fly: Top stock stories for Friday
Stocks on Wall Street began the final trading day of May with slight losses. The averages began to pick up downside momentum after revised GDP numbers confirmed expectations that the economy shrank in the first quarter of the year. The Wall Street adage of “sell in May, then go away” appeared to be taking hold as the S&P broke a support level and took the other averages with it. Investors are now concerned about a June swoon, as it is historically one of the worst performing months of the year. ECONOMIC EVENTS: In the U.S., the second estimate of gross domestic product showed it shrank at a 0.7% seasonally adjusted annual rate in the first quarter. This was down from the previous estimate that output grew 0.2% from January through March, but better than the revision to a 1% decline that had been forecast by analysts. The Chicago PMI unexpectedly dropped 6.1 points to 46.2 in May, versus expectations for it to have risen to a reading of 53. The University of Michigan's consumer sentiment reading came in with a 90.7 reading for the final May print, which was up from the preliminary 88.6 reading for the month but down from April's 95.9 figure. COMPANY NEWS: Shares of Humana (HUM) jumped $36.24, or 20.31%, to $214.65 after The Wall Street Journal said the company has hired Goldman Sachs (GS) to help it explore a potential sale after receiving indications of takeover interest. Some of the Journal's sources reportedly said Aetna (AET) and Cigna (CI) are among possible bidders for Humana. Bloomberg then said Humana's sale exploration came after Cigna made a takeover approach. Leerink analyst Ana Gupte wrote in a note to investors on May 12 that consolidation in the industry remains likely, adding that a deal between Aetna and either Cigna or Humana were both "meaningfully accretive" and "imminent" possibilities. MAJOR MOVERS: Among the notable gainers was Heron Therapeutics (HRTX), which gained $7.41, or 60%, to $19.76 after the company reported positive top-line data from a Phase 3 marketing study looking at Sustol as part of a 3-drug regimen for the prevention of delayed-onset chemotherapy-induced nausea and vomiting following administration of highly emetogenic chemotherapy agents. Also higher was Altera (ALTR), which advanced $1.88, or 4%, to $48.85 after reports from The New York Post and Financial Times claimed the company is near a deal to be acquired by chipmaking giant Intel (INTC) for up to $54 per share. Reuters, meanwhile, revised its prior report to indicate the potential price of the deal could be close to $16B. Among the noteworthy losers was Abercrombie & Fitch (ANF), which fell $1.63, or 7.38%, to $20.47 after Janney Capital downgraded the stock to Sell from Hold and warned the company's comparative sales may continue to drop year-over-year as it changes nearly every aspect of its business. Also lower were shares of Bristol-Myers Squibb (BMY), which dropped $4.55, or 6.58%, to $64.60 after the company reported data from a Phase III study evaluating Opdivo in previously-treated patients with advanced, non-squamous non-small cell lung cancer. Biotech analyst Mark Schoenebaum reportedly said Bristol-Myers' data from its Checkmate 057 study opens the door for lung cancer competition from Merck (MRK) and Roche (RHHBY), according to TheStreet's Adam Feuerstein. INDEXES: The Dow dropped 115.44, or 0.64%, to 18,010.68, the Nasdaq lost 27.95, or 0.55%, to 5,070.03, and the S&P 500 fell 13.40, or 0.63%, to 0.63.
16:00 EDTFBOptions Update; May 29, 2015
Subscribe for More Information
14:58 EDTBMYBristol-Myers Opdivo data opens door for competition, Schoenebaum says
Subscribe for More Information
14:49 EDTBMYBristol-Myers tumbles in late afternoon trading
Subscribe for More Information
14:27 EDTBMYBristol-Myers down 4.5% after reporting on Opdivo trials
Subscribe for More Information
14:06 EDTBMYBristol says Opdivo demonstrates anti-tumor activity in hepatocellular carcinoma
Subscribe for More Information
14:04 EDTBMYBristol-Myers says Opdivo demonstrates superior OS versus standard of care
Bristol-Myers Squibb announced that Opdivo is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care, or docetaxel, in an open-label, randomized Phase III study evaluating previously-treated patients with advanced, non-squamous non-small cell lung cancer, or NSCLC. A 27% reduction in the risk of progression or death – the primary study endpoint – was reported for Opdivo versus docetaxel based upon a hazard ratio of 0.73. Opdivo was associated with a doubling of overall median survival across the continuum of PD-L1 expression, starting at 1% level of expression, in the trial. The safety profile of Opdivo in CheckMate -057 was favorable versus docetaxel with grade 3–5 treatment-related adverse events reported in 10% of patients who were treated with Opdivo versus 54% in the docetaxel arm. These data will be featured today, May 29, during the 51st Annual Meeting of the American Society of Clinical Oncology press briefing and presented during a clinical science symposium on Saturday, May 30, the company noted.
09:35 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL INTC VLO FB HFC AMZN FB BRCM FCX
06:16 EDTFBFacebook implied volatility of 20 at lower end of index mean range
Subscribe for More Information
May 28, 2015
16:03 EDTFBOptions Update; May 28, 2015
Subscribe for More Information
15:11 EDTBMYBristol-Myers to hold a conference call
Subscribe for More Information
12:31 EDTFBStocks with call strike movement; PBR FB
Petrobras (PBR) October 10 call option implied volatility increased 2% to 52, Facebook (FB) September 90 call option implied volatility increased 2% to 26 according to IVolatility.
11:22 EDTBMYCatalyst Pharmaceutical names Richard Daly as interim Chief Commercial Officer
Subscribe for More Information
10:55 EDTFBGoPro rises after confirming plans to enter drone, VR markets
Shares of GoPro (GPRO) are rising after the action camera maker confirmed it is developing a camera array for virtual reality filming and is also making its own drone for consumers. WHAT'S NEW: GoPro is developing a product that can create video which can be viewed on virtual reality headsets, GoPro CEO Nick Woodman said at the Code Conference, according to Re/code. Called a Six-Camera Spherical Array, the device uses six of GoPro's Hero4 cameras and a product from Kolor, a virtual reality software company GoPro acquired in April. GoPro is also building its own drone geared to consumers, Woodman said, according to Re/code. However, the company will continue to provide cameras to other drone makers, the website noted. ANALYST REACTION: In a note to investors earlier today, Piper Jaffray analyst Erinn Murphy said that GoPro's virtual reality product should be available in the second half of this year and cost $500-$1,500. The drone is expected to be available in the first half of next year and is likely to be sold for $500-$2,500, the analyst stated. GoPro's expansion into the drone and virtual reality markets could undermine bears' contention that GoPro's total available market is low, according to Murphy. Drones and virtual reality should have total available markets of over $5B by 2020 and over $65B by 2025, respectively, estimated the analyst, who kept a $68 price target and Overweight rating on GoPro. Meanwhile, Stifel analyst Jim Duffy wrote that the virtual reality product will have only a minimal impact on GoPro's results in 2015 and 2016. However, the drone offering could increase its 2016 earnings per share by 20c-30c if it is launched in the beginning of the year, according to Duffy, who kept a Hold rating on the stock. WHAT'S NOTABLE: In a note to investors yesterday, well-known Piper Jaffray analyst Gene Munster called virtual reality and augmented reality "the next mega tech themes through 2030." Users will be able to enjoy gaming, live sports, concerts, "immersive cinema," and social experiences using virtual reality, he predicted. Facebook (FB), Google (GOOG,GOOGL) and Apple (AAPL) are likely to benefit from this trend, Munster believes. PRICE ACTION: In mid-morning trading, GoPro climbed nearly 8% to $57.43.
10:02 EDTFBSandvine: Netflix accounts for 36.5% of peak Internet traffic, Variety reports
Subscribe for More Information
09:34 EDTFBActive equity options trading on open
Subscribe for More Information
08:06 EDTFBFacebook bringing Internet.org service to Pakistan with Telenor
Subscribe for More Information
06:07 EDTFBFacebook implied volatility of 20 at lower end of index mean range
Subscribe for More Information
May 27, 2015
16:03 EDTFBOptions Update; May 27, 2015
iPath S&P 500 VIX Short-Term Futures down 82c to 18.56 Option volume leaders: AAPL KORS BRCM MCD FB MNKD AAL YHOO BAC MU ANF S EOX
10:38 EDTFBFacebook testing Yelp-like feature for restaurant pages, ClickZ reports
Subscribe for More Information
10:32 EDTFBTwitter beats LinkedIn as top social media site for salespeople, Forbes reports
In a survey conducted by Forbes with a client, Twitter (TWTR) beat LinkedIn (LNKD) to become the top social media network for salespeople. When it came to sales prospecting, Twitter was "slightly more valuable" than LinkedIn, according to the survey, though both sites beat out Facebook (FB) and Google (GOOG). Reference Link
09:38 EDTFBActive equity options trading on open
Subscribe for More Information
09:17 EDTFBFacebook's Oculus acquires Surreal Vision, terms not disclosed
Facebook-owned Oculus announced in a blog post yesterday the acquisition of Surreal Vision. Oculus explains, "Surreal Vision is one of the top computer vision teams in the world focused on real-time 3D scene reconstruction – generating an accurate representation of the real world in the virtual world. Great scene reconstruction will enable a new level of presence and telepresence, allowing you to move around the real world and interact with real-world objects from within VR." Reference Link
08:39 EDTFBSony purchases Optical Archive, WSJ reports
Subscribe for More Information
06:13 EDTFBTech companies look for ways to fend off activist investors, WSJ reports
Subscribe for More Information
06:01 EDTFBSnapchat CEO says company 'needs to IPO," Business Insider reports
Subscribe for More Information
May 26, 2015
18:32 EDTFBFacebook India offers content creators exclusivity deals, Economic Times says
Subscribe for More Information
16:01 EDTFBOptions Update; May 26, 2015
Subscribe for More Information
09:38 EDTBMYuniQure reports collaboration with Bristol-Myers closed, triggers $50M payment
uniQure (QURE) announced the closing of its strategic collaboration with Bristol-Myers Squibb (BMY) to develop gene therapies for cardiovascular disease. The transaction was previously announced on April 6. Under the terms of the agreement, Bristol-Myers Squibb will make near-term payments of approximately $100M, including an initial upfront payment of $50M upon closing of the transaction, a $15M payment upon selection of three collaboration targets, in addition to S100A1, to be made within three months of closing, and an initial equity investment in uniQure representing 4.9% of the total number of shares outstanding following such issuance, at a purchase price of $33.84 per share, or approximately $37M in total. The initial equity investment is expected to close on June 12. Bristol-Myers-Squibb will acquire an additional 5.0% ownership before December 31, at a 10% premium, and has been granted two warrants, each to acquire up to an additional 5% equity interest, at a premium, based on additional targets being introduced into the collaboration. The parties have also agreed to enter into a supply contract, under which uniQure will undertake manufacturing of all gene therapy products under the collaboration. uniQure will also be eligible to receive research, development and regulatory milestone payments, including up to $254M for the lead S1A001 therapeutic and up to $217M for each other gene therapy product potentially developed under the collaboration. Additionally, uniQure is eligible to receive net sales based milestone payments and tiered single to double-digit royalties on product sales.
07:37 EDTBMYBristol-Myers opportunity in renal cell over $2B, says JPMorgan
Subscribe for More Information
07:19 EDTFBFacebook being scrutinized on several fronts in Europe, NY Times reports
In recent months, several different European regulators have been examining facets of Facebook's (FB) operations and it remains to be seen whether the social network operator has learned from the past mistakes of companies such as Intel (INTC), Microsoft (MSFT) and Google (GOOG) in terms of navigating Europe’s legal system, said The New York Times. The European Union is looking into whether Facebook unfairly favors its own services, the region’s top court will issue a preliminary decision next month on whether Facebook can continue transferring user data between Europe and the U.S. and a number of EU data protection watchdogs are questioning Facebook’s privacy settings, the report noted. Reference Link
May 22, 2015
16:00 EDTFBOptions Update; May 22, 2015
Subscribe for More Information
10:52 EDTBMYJPMorgan says Actavis shares cheap compared to peers
Subscribe for More Information
10:33 EDTFBFacebook management to meet with Oppenheimer
Subscribe for More Information
09:34 EDTFBActive equity options trading on open
Active equity options trading on open: AAPL BABA AMZN FB MU BIDU SDRL BAC INTC EXPE CHK FEYE
07:33 EDTBMYBristol-Myers receives positive CHMP opinion for Nivolumab
Subscribe for More Information
May 21, 2015
19:44 EDTFBGoogle advertising head remarks that larger phones may help mobile ads, WSJ says
In a Wall Street Journal interview at the San Francisco ad:tech conference, Google (GOOG) advertising chief Sridhar Ramaswamy commented on the conversation rate from mobile ad viewership to actual mobile sales, stating, "As phones get bigger the [screen] space issue becomes less challenging... [My six-inch phone] is essentially a tablet. People’s ability to navigate sites and fill out forms and such goes up tremendously." Ramaswamy also offered commentary on Facebook's (FB) advertising metrics, asking, "How many of Facebook’s video views are engaged views?" The Journal notes that Google's YouTube waits 30 seconds to register a video view, while Facebook counts a view "more quickly." Reference Link
16:00 EDTFBOptions Update; May 21, 2015
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
08:02 EDTFBDuPont Fabros expands relationship with Facebook at ACC7 data center
Subscribe for More Information
07:37 EDTBMYPfizer replaces AbbVie as top global pharma pick at Jefferies
Subscribe for More Information
May 20, 2015
16:00 EDTFBOptions Update; May 20, 2015
iPath S&P 500 VIX Short-Term Futures up 3c to 19.19. Option volume leaders: AAPL AAL YHOO DAL FB BABA UAL BAC TWTR LUV C TSLA GE MU
14:04 EDTFBFacebook acquires web publisher tool maker Tugboat Yards
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
09:01 EDTBMYBristol-Myers receives amended breakthrough therapy designation for daclatasvir
Subscribe for More Information
07:21 EDTBMYUBS to hold a conference
Subscribe for More Information
May 19, 2015
16:01 EDTFBOptions Update; May 19, 2015
iPath S&P 500 VIX Short-Term Futures down 27c to 19.17. Option volume leaders: AAPL BAC WMT MSFT FB TWTR MNKD NFLX T PBR
09:37 EDTFBActive equity options trading on open
Subscribe for More Information
08:57 EDTBMYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:56 EDTBMYGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
07:45 EDTBMYJacobs Engineering receives contract from Bristol-Myers
Jacobs Engineering (JEC) received a contract from Bristol-Myers Squibb Company (BMY) to provide construction management services for a new large-scale biologics manufacturing facility in Cruiserath, County Dublin, Ireland. Jacobs is also providing architectural and engineering services for the facility, which is being built to produce multiple therapies for the company’s robust and growing portfolio of approved and investigational biologic medicines, and to increase Bristol-Myers Squibb’s biologics manufacturing capacity. The new facility is expected to include multiple large scale bioreactors, a purification area, as well as office and laboratory space. Bristol-Myers Squibb’s Board of Directors has approved initial funding that will support the first phase of the project, with the full cost of the facility expected to be finalized in the second half of 2015. The facility is estimated to be operational in 2019.
May 18, 2015
16:00 EDTFBOptions Update; May 18, 2015
Subscribe for More Information
11:16 EDTFBFacebook says move to digital ads from TV and print is 'in early days'
Subscribe for More Information
10:37 EDTFBFacebook ramps up interest in games, The Information reports
Subscribe for More Information
09:36 EDTFBActive equity options trading on open
Subscribe for More Information
08:22 EDTFBVerizon deal has multiple positive catalysts, says Wells Fargo
Subscribe for More Information
07:27 EDTFBJPMorgan to hold a conference
Subscribe for More Information
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use